相关实验视频

Updated: Oct 21, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

晚期恶性瘤患者的TQB2450:来自I期剂量升级和扩展研究的结果

Junli Xue¹, Liqiong Xue¹, Wenbo Tang¹

¹Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.

Therapeutic advances in medical oncology

|January 8, 2024

概括

TQB2450,一种针对编程细胞死亡联体1的新型抗体,在晚期癌症中显示出可控的安全性. 观察到早期临床活性,在I期试验中,疾病控制率为52.50%.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
药理学药理学是指药理学的学科.

背景情况:

免疫检查点抑制剂 (ICI) 在各种癌症中提供显著的临床益处.
TQB2450是一种新的单克隆抗体,旨在向编程细胞死亡带1 (PD-L1).
临床前研究表明,TQB2450.0.的安全性和有效性很有希望.

研究的目的:

评估TQB2450.0.的安全性,耐受性,药理动力学 (PK) 和免疫性.
评估TQB2450在患有晚期恶性瘤的患者中的初步抗瘤活性.
为了确定TQB2450.5的最大耐受剂量 (MTD) 和剂量限制毒性 (DLT).

主要方法:

一个第一阶段,首次在人体上进行的研究,涉及3+3剂量升级 (1-30 mg/kg) 和剂量扩展 (1200 mg) 阶段.
符合条件的患有晚期恶性瘤的患者每3周内接受静脉注射TQB2450.
主要终点包括安全性,MTD和DLT;次要终点是PK,免疫性和响应率.

主要成果:

在40名注册患者中,没有达到DLT或MTD.
与治疗相关的3级以上的不良事件发生在27.50%的患者中;最常见的是AST升高,白血病和贫血.
客观应答率为5.00%,疾病控制率为52.50%,中位数无进展生存期为2.69个月.

结论:

TQB2450证明了可管理的安全概况.
该药物表现出有利的药理动力学和免疫性特征.
晚期恶性瘤的早期临床活性表明TQB2450.5的治疗潜力.

关键词:

在TQB245050中使用.先进的恶性瘤.第一个阶段I阶段.编程细胞死亡连接体 1 编程细胞死亡连接体在安全方面,安全是安全的.

更多相关视频

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...